Liver Surgery for Breast Cancer That Has Spread to the Liver: What the Evidence Really Shows

Table of Contents

• Key Points
• Background: Why This Question Matters
• The Spread of Breast Cancer: Understanding the Numbers
• Why Doctors Have Been Hesitant to Operate
• How This Review Was Conducted
• What the Published Reviews Found
• One Center's Experience: The Ruiz Nomogram
• Comparative Studies: Surgery Versus Chemotherapy Alone
• The Cost-Utility Analysis: Is Surgery Worth the Cost?
• Discussion: Weighing the Evidence
• Clinical Implications: What This Means for Patients
• Limitations: What the Evidence Couldn't Prove
• Recommendations for Patients and Doctors
• Frequently Asked Questions
• Source Information

Key Points

• Across studies, 5-year survival after liver resection for breast cancer liver metastases ranges from 21% to 58%.
• Three of four retrospective comparative studies found better survival with surgery than chemotherapy alone, but evidence is weak.
• A longer interval between breast cancer treatment and liver metastasis diagnosis is the most consistent predictor of better survival.
• Patients with ER+ tumors responding to systemic therapy appear to gain most from liver surgery; triple-negative tumors have worse prognosis.
• Surgery may be offered when complete removal with clear margins is possible and at least 30% of healthy liver can be preserved.

Background: Why This Question Matters

Breast cancer (BC) is one of the most common cancers in women worldwide. In 2018, the estimated age-adjusted annual incidence of breast cancer in 40 European countries was 145.2 cases per 100,000 women, with a mortality rate of 32.8 per 100,000 (1). These numbers mean that breast cancer remains the leading cause of cancer-related death in European women (2), and the primary cause of those deaths is metastatic spread — cancer that travels beyond the breast to other organs.

The incidence of breast cancer actually increased after mammography screening became routine, and it continues to grow as the population ages. The good news is that mortality rates have decreased in most Western countries, thanks to better treatment options and earlier detection. More women are surviving their initial breast cancer diagnosis, which raises an important question: what happens when the cancer later shows up in distant organs?

Survivors are typically followed with regular physical examinations and mammography — every 3 to 6 months for the first 3 years, every 6 to 12 months for the next 2 years, and annually after that. Notably, routine blood counts, chemistry panels, bone scans, chest X-rays, liver ultrasounds, CT scans, PET scanning, magnetic resonance imaging, and tumor marker tests are not recommended for routine follow-up in an otherwise asymptomatic patient (4). This means that a systematic search for distant metastases is rarely performed, and liver metastases are often discovered only when symptoms appear.

The Spread of Breast Cancer: Understanding the Numbers

Approximately 30% of patients with breast cancer will develop metastases at some point during the course of their disease (6). The liver is the third most frequent site of metastatic spread, after lymph nodes and the lung. However, only 5–25% of patients will have isolated breast cancer liver metastases (LM) — meaning the liver is the only organ affected by the spread. This subset of patients could potentially be eligible for liver surgery or other liver-directed therapies, and their numbers are substantial.

Early research revealed striking differences in survival based on where breast cancer metastasized (5). Patients who developed bone metastases had a median survival of 48 months, with a strong positive response to first hormonal therapy, which was effective in 87% of patients (median response duration: 10 months).

Chemotherapy was also effective in 93% of bone metastasis patients (median response duration: 11 months). By contrast, patients who developed metastases in any other organ had a significantly shorter median survival of just 17 months (5). These numbers shaped clinical thinking for decades and continue to influence how doctors approach metastatic breast cancer today.

Despite the large number of potential candidates, actual surgical treatment is rare. A collective series from 8 international centers over a 24-year period collected only 119 cases of liver resections (LRs) performed for breast cancer liver metastases (6). To put that in perspective: if approximately 10% of women with breast cancer will develop metastatic disease confined to the liver, an estimated 96,000 cases may have arisen in the United States alone over the same period (8). The gap between the theoretical number of potential candidates and the actual number of surgeries performed is enormous.

Why Doctors Have Been Hesitant to Operate

Several factors explain why liver surgery for breast cancer metastases has remained controversial. First, metastatic breast cancer has historically been defined as a "systemic" disease — meaning the cancer is considered to be throughout the body, not just in one spot. If that is true, then removing a liver tumor with surgery might not change the overall outcome.

Second, there are important differences between breast cancer liver metastases and colorectal cancer liver metastases, and these differences affect treatment decisions. The table below summarizes the key comparisons from the original article:

• Effective chemotherapy: For breast cancer liver metastases, effective chemotherapy has been established for a long time and is typically used as first-line therapy. For colorectal cancer liver metastases, effective chemotherapy was established only recently.
• Role of liver surgery: In breast cancer, surgery is considered only after first-line chemotherapy — even when the disease appears readily resectable. In colorectal cancer, surgery is the preferred first-line treatment.
• Surgical treatment: For breast cancer, liver surgery is often perceived as excessively invasive, especially since breast cancer management has evolved toward more conservative approaches. For colorectal cancer, surgery is standard practice.

Third, the historical belief that bone metastases respond well to treatment (with the 48-month median survival noted above) while "visceral" metastases (those in organs like the liver) are rapidly fatal became deeply embedded in clinical practice. This mindset discouraged aggressive local treatment for liver disease.

How This Review Was Conducted

Dr. Gian Luca Grazi, a liver surgeon at the IRCCS Regina Elena National Cancer Institute in Rome, Italy, conducted this narrative review to evaluate the available scientific evidence on liver resections for breast cancer liver metastases. The review was based on case series, literature reviews, comparative studies, and cost-utility analyses selected according to criteria regarding surgery, possible prognostic factors, and evaluation of long-term survival.

One key strategy researchers use when individual studies are too small or inconsistent is to combine their findings in systematic reviews. Between 2006 and 2018, ten such reviews were published, and this article analyzes them in detail. Here is a breakdown of those ten reviews:

• Elias (2006, HPB): reviewed 9 studies on liver resection, minimum 10 patients per study
• Howlader (2011, International Journal of Surgery): reviewed 11 studies, minimum 9 patients per study
• Chua (2011, European Journal of Cancer): reviewed 19 studies, minimum 10 patients per study
• Vogl (2013, European Radiology): reviewed 8 studies on thermal ablation (using heat to destroy tumors)
• Vertriest (2015, Digestive Surgery): reviewed 17 studies on liver resection
• Fairhurst (2016, The Breast): reviewed 33 studies, minimum 5 patients per study
• Golse (2017, Clinical Breast Cancer): reviewed 18 principal series published since 2000
• Yoo (2017, The Breast): reviewed 43 studies on liver resection
• Ercolani (2018, Digestive Surgery): reviewed 10 studies, minimum 40 patients per study
• Tasleem (2018, Irish Journal of Medical Science): reviewed 25 studies on liver resection

Notably, the stricter the inclusion criteria (for example, requiring larger patient numbers), the fewer studies qualified for review. When the threshold was set at more than 40 cases, only 10 series were eligible for analysis (20).

What the Published Reviews Found

The most obvious problem across all this literature is the striking inhomogeneity of the reported data. Postoperative mortality rates (death within 30 days or during the hospital stay after surgery) ranged from 0% to 5%, and 5-year overall survival rates ranged from 21% to 58%. This wide variation raises serious questions about which patients were selected for surgery in different centers.

The largest review, published by Yoo and colleagues in 2017 in a non-surgical journal (19), identified 1,705 potentially relevant citations and ultimately included 43 papers meeting defined search criteria. Its findings are worth examining closely:

• 30-day mortality rate: 0.7% (6 deaths out of 918 patients across studies that reported this data)
• Median 3-year overall survival: 56%
• Median 5-year overall survival: 37%
• Only 21 out of 43 studies (48.8%) reported any selection criteria for surgery
• Only 6 studies (14.0%) included more than 50 patients
• Only 22 out of 43 papers (51.2%) investigated possible prognostic factors

The prognostic factors that were analyzed varied widely from paper to paper, and many variables reported in one study were absent in another. Even a simple variable like age was reported in only 15 of the 22 studies (68.2%) that examined prognostic factors. The influence of age was also inconsistent: 12 studies found age had no effect on long-term results; 2 studies reported better outcomes in patients over 50 years old (22,23); and 1 study found better survival in patients younger than 50 (24).

One single factor was shown to have a consistent positive influence on survival: the prolonged interval between breast cancer treatment and the diagnosis of liver metastases (19). In other words, the longer a patient stayed cancer-free after her initial breast cancer treatment before liver metastases appeared, the better her chances of surviving after liver resection.

Because study periods were very long — often spanning 10 to 20 years just to collect enough cases — potential bias was introduced in terms of patient selection, cancer staging, and surgical technique. The heterogeneity across studies makes it difficult for readers to draw clear conclusions about who should be offered surgery.

One Center's Experience: The Ruiz Nomogram

Among the many single-center reports, one stands out. The paper by Ruiz and colleagues describes experience with 162 hepatectomies (liver resections) performed in 139 consecutive women with breast cancer liver metastases (25). This study identified negative factors (those that shorten survival) and positive factors (those that improve survival):

Negative predictors of survival (factors associated with worse outcomes):

• More than 1 liver metastasis
• Being "triple negative" — meaning the tumor is negative for estrogen receptors, progesterone receptors, and HER2/Neu receptors
• Microscopic vascular invasion (cancer cells found in blood vessels under the microscope)

Positive predictors of survival (factors associated with better outcomes):

• Negative resection margins (no cancer cells at the edge of the removed tissue)
• Administration of hormonal therapy before and after liver resection
• Performance of repeated hepatectomy (a second liver surgery if cancer returned in the liver)

This is the only paper that provides a clinical tool — a nomogram — to predict 3- and 5-year survival after hepatectomy for breast cancer liver metastases. A nomogram is a visual calculator that combines multiple patient and tumor characteristics to estimate outcomes. The author notes that for patient selection, it would be substantially better to be able to predict outcomes using data available before surgery rather than after, since factors like resection margins are only known after the operation.

Comparative Studies: Surgery Versus Chemotherapy Alone

The strongest evidence for any treatment's effectiveness typically comes from comparative studies, ideally randomized controlled trials. Unfortunately, no randomized trials exist for liver surgery in breast cancer liver metastases. The four comparative studies that have been published are all retrospective, and their overall scientific strength is considered weak. Here is what each one found.

Study 1: Mariani and colleagues (2013, France) (7). This retrospective case-control study evaluated 51 patients treated medically compared with 49 patients treated with surgery (out of 100 total patients), matched for age at breast cancer diagnosis, year of diagnosis, time between breast cancer diagnosis and first liver metastasis, TNM stage of the original breast cancer, hormone receptor status, and whether the tumor was ductal or lobular histology. The criteria for surgery were:

1. Resectable liver metastases (≤4 metastases)
2. Stable disease or disease responding to chemotherapy and/or hormone therapy
3. Performance status (a measure of daily functioning) of 0–1
4. Bone metastases allowed only if they did not grow during treatment

The study demonstrated a significantly better survival in the surgically treated group. The best predictors of survival for the whole cohort of 100 patients were: negative lymph node status of the primary breast tumor, receiving a single course of chemotherapy, having no bone metastases at the time of liver metastasis diagnosis, and undergoing liver surgery.

Study 2: Polistina and colleagues (2013) (26). This study compared 38 patients treated with chemotherapy over a 7-year period to 26 patients with isolated liver metastases who received liver-directed therapies. Of those 26, twelve underwent liver resection when the disease was confined to one lobe of the liver (regardless of the number of lesions), and 14 underwent percutaneous radiofrequency ablation (using heat to destroy tumors) when the metastases were in both lobes without any lesion larger than 6 centimeters. The treated patients had prolonged survival compared with the control group: median survival of 21.1 months versus 9.7 months. Patients treated by liver resection performed better than those treated by local ablation.

Study 3: Sadot and colleagues (2016) (27). This study drew from a database of 2,150 patients over a 23-year period evaluated by a multidisciplinary tumor board. Of these, 167 patients met inclusion criteria: 69 patients (41%) in the surgical cohort treated with liver resection and/or ablation, and 98 patients (59%) in the medical cohort receiving medical therapy alone. A propensity score analysis was used to control for selection bias. Importantly, this study did not show any benefit in performing liver-directed therapies compared with medical therapy alone. However, the authors noted that surgical therapy provided at least a temporary disease-free status, giving patients a chance to discontinue toxic therapy, at least for some time.

Study 4: Abbas and colleagues (2017) (28). This report from a UK tertiary center's multidisciplinary tumor board meeting included 61 patients with isolated liver metastases: 23 treated with surgery, 11 with percutaneous radiofrequency ablation, and 27 with chemotherapy alone. Liver resection or ablation was offered when the disease was considered resectable at first evaluation or when the disease responded to systemic chemotherapy and then became resectable. Better survival was reported for patients who had surgery or ablation compared with chemotherapy alone. The presence of extrahepatic disease (cancer outside the liver, in addition to the liver metastases) considerably reduced survival after any treatment.

In summary: three out of the four comparative studies report better survival for patients who underwent liver resection or ablation compared with chemotherapy alone. However, all four studies are retrospective, have different inclusion criteria, and only one (Mariani) reported clear inclusion criteria for the medical control group. Only one study (Mariani) included liver resection alone, while the others combined resection with ablation. The scientific strength of the evidence is therefore limited.

The Cost-Utility Analysis: Is Surgery Worth the Cost?

Only one cost-utility analysis has been published on this topic (29), and it provides an economic perspective on the treatment decision. The analysis examined 2 different scenarios with 3 different strategies:

• Strategy A: Liver resection followed by postoperative conventional systemic therapy
• Strategy B: Conventional systemic chemotherapy alone
• Strategy C: A newer systemic therapy alone (compared in the second scenario)

The findings were nuanced. For patients with ER+ tumors (estrogen receptor positive), liver resection plus systemic therapy was more cost-effective than systemic therapy alone. However, for patients with HER2+ tumors, the performance of hepatectomy plus systemic chemotherapy had a cost-effectiveness comparable to systemic therapy alone. Furthermore, liver resection plus standard systemic chemotherapy was more cost-effective when compared with the administration of newer, likely more expensive systemic chemotherapeutic agents.

Two of the three scenarios considered favored surgery followed by conventional chemotherapy.

The analysis also reinforced the importance of tumor biology. The diagnosis of an ER− primary tumor (estrogen receptor negative) and preoperative disease progression (cancer growing despite systemic treatment) were both associated with poor outcomes after hepatic resection. Conversely, among patients with ER+ tumors who had stable or responsive disease on systemic therapy, surgical therapy was strongly associated with improved survival compared with chemotherapy alone.

Discussion: Weighing the Evidence

Liver resections for breast cancer liver metastases remain an unresolved question for liver surgeons. After analyzing the available literature — the recent reviews, the four comparative studies, and the one cost-utility analysis — the author concludes that there are no strong lines of evidence for including surgical therapy within the advised treatments for these patients.

Current guidelines state that the first approach for metastatic breast cancer is systemic chemotherapy, and this is what currently takes place in clinical practice. The scientific literature does not support any particular feature of breast cancer liver metastases as a definitive criterion for surgery (18). The heterogeneity in clinical variables, patient numbers, and observation periods across studies is simply too great to draw firm conclusions.

Surprisingly, when indications for surgery were reported in the comparative studies, the presence of multiple liver nodules was not consistently considered a contraindication. Mariani performed surgery in the presence of 4 or fewer metastases, while Polistina performed hepatectomy when metastases were confined to one lobe, regardless of the number of lesions.

The author also questions the value of continuing to publish more single-center retrospective reviews on this topic, given how little they have contributed to resolving the core question of whether surgery truly helps these patients.

Clinical Implications: What This Means for Patients

For patients diagnosed with breast cancer liver metastases, this review offers both clarity and caution. The evidence does not support surgery for every patient, but it does suggest that a select group may benefit. Based on the available data, the author proposes that surgery can be considered when the following conditions are met:

• Radical surgery is possible: The operation must achieve R0 margins, meaning no cancer cells are visible at the edges of the removed tissue under a microscope.
• At least 30% of the liver can be saved: The remaining liver must be enough to support normal liver function, with its vascular (blood vessel) and biliary (bile duct) connections intact.
• Stable skeletal metastases are not a contraindication: If bone metastases exist but are stable (not growing during treatment), surgery on the liver may still be appropriate.
• A prolonged interval since the primary breast cancer treatment: The time between treatment of the original breast cancer and the diagnosis of liver metastases is the only reliable prognostic criterion available. A longer disease-free interval is associated with better outcomes after surgery.

Tumor biology also matters. Patients with ER+ tumors that are stable or responding to systemic therapy appear to benefit most from liver surgery. Conversely, patients with triple-negative tumors, estrogen receptor negative tumors, or disease that is progressing despite chemotherapy are less likely to benefit.

Limitations: What the Evidence Couldn't Prove

This review has important limitations that must be acknowledged:

• No randomized controlled trials exist on this topic, so the strongest form of medical evidence is simply unavailable.
• All comparative studies are retrospective, meaning they looked backward at medical records rather than prospectively assigning patients to treatments.
• The published studies suffer from significant heterogeneity in patient selection criteria, cancer staging, surgical technique, and length of follow-up.
• Study periods are often extremely long — spanning decades — to collect enough cases, which introduces bias from changes in chemotherapy, imaging, and surgical approaches over time.
• The number of patients in most studies is small, with only 6 out of 43 studies in the largest review including more than 50 patients.
• Most series come from single centers and lack defined, consistent selection criteria for surgery.

Because of these limitations, the review cannot definitively prove whether liver resection improves survival for breast cancer liver metastases. The author is explicit that indications for surgery remain a matter of debate, and the strength of the existing evidence is weak.

Recommendations for Patients and Doctors

For patients facing this diagnosis, the review points to several practical takeaways:

1. Seek a multidisciplinary tumor board evaluation. The comparative studies indicate that decisions about liver surgery are best made by a team including medical oncologists, surgeons, radiologists, and pathologists with experience in both breast cancer and liver disease.
2. Systemic therapy comes first. Current guidelines recommend chemotherapy or hormone therapy as the initial approach for metastatic breast cancer, and this review does not overturn that guidance.
3. Ask about your tumor's biology. Knowing your hormone receptor status (ER, PR) and HER2 status is critical. Patients with ER+ tumors that respond to systemic therapy appear to have the most to gain from liver surgery.
4. Understand the timing factor. The interval between your original breast cancer treatment and the diagnosis of liver metastases matters. A longer disease-free interval is associated with better outcomes after surgery.
5. Discuss the surgical details. If surgery is proposed, ask whether the goal is complete removal with clear margins (R0 resection) and whether at least 30% of your liver can be preserved. Stable bone metastases do not automatically rule out liver surgery.
6. Weigh the option carefully if your disease is progressing. Preoperative disease progression while on systemic therapy was associated with poor outcomes. Triple-negative tumors and estrogen receptor negative tumors also carry a worse prognosis after surgery.
7. Know the survival statistics. Across published studies, median 5-year survival after liver resection for breast cancer metastases is around 37%, with individual studies ranging from 21% to 58%. Postoperative mortality is generally low, around 0.7% in the largest review.

Ultimately, the decision to pursue liver surgery for breast cancer liver metastases must be individualized. This review confirms that surgery can be safe and that some patients experience prolonged survival and periods free from toxic chemotherapy. However, the evidence

Frequently Asked Questions

Can breast cancer liver metastases be treated with surgery?

Yes, in carefully selected patients. Surgery can be considered when the liver tumor can be completely removed with clear margins and at least 30% of healthy liver can be preserved. However, the evidence is not definitive, and surgery is not appropriate for every patient. A multidisciplinary team should evaluate your individual situation.

What are survival rates after liver surgery for breast cancer metastases?

Across published studies, median 5-year survival after liver resection is about 37%, with individual studies ranging from 21% to 58%. Postoperative death within 30 days is generally low, around 0.7% in the largest review. Your outlook depends on tumor biology, response to systemic therapy, and other individual factors.

Does surgery improve survival compared with chemotherapy alone?

Three out of four retrospective comparative studies reported better survival with surgery than with chemotherapy alone, but one study found no benefit. These studies are not randomized and are considered weak evidence. Surgery may offer a period free from chemotherapy, but it is not proven to extend survival in all patients.

Which patients benefit most from liver surgery?

Those with estrogen receptor positive tumors that are stable or responding to systemic therapy appear to gain the most. A longer interval between breast cancer treatment and liver metastasis diagnosis is also associated with better outcomes. Conversely, patients with triple-negative or estrogen receptor negative tumors, or disease progressing during chemotherapy, are less likely to benefit.

What is the risk of liver surgery?

In published studies, postoperative death within 30 days ranged from 0% to 5%, and the largest review reported a rate of 0.7%. Individual risk depends on your overall health, the extent of liver resection, and the remaining liver function. Surgery also carries risks of complications such as bleeding, infection, or bile leakage.

Is it safe to have liver surgery if I also have bone metastases?

Stable bone metastases are not considered a contraindication to liver surgery, according to one comparative study. However, bone metastases that are growing during treatment are associated with worse survival. Your multidisciplinary team will assess whether bone disease is controlled before recommending liver surgery.

Why is liver surgery for breast cancer metastases controversial?

Breast cancer is often viewed as a systemic disease, so some doctors question whether removing liver tumors changes overall outcomes. There are no randomized controlled trials, and existing studies vary widely in patient selection and results. Guidelines recommend systemic therapy as the first approach, and surgery is considered only in certain circumstances.

Should I get a second opinion before deciding whether to have liver surgery for breast cancer that has spread to my liver?

Yes. Evidence on liver resection for breast cancer liver metastases is not definitive: no randomized trials exist, the four comparative studies are retrospective and weak, and 5-year survival after surgery ranges widely from 21% to 58%. Surgery appears most helpful when complete removal with clear margins is possible, at least 30% of liver remains, the tumor is ER+ and stable on systemic therapy, and there was a long interval before liver metastases appeared. A second opinion can help clarify whether you fit that profile and whether surgery or chemotherapy alone is the better choice. Diagnostic Detectives Network provides independent expert second opinions.